Telix

Telix Opens European Radiopharmaceutical Production Facility

Retrieved on: 
Thursday, June 8, 2023
Seneffe, GMP, Heart, Radiation, Employment, Therapy, Cyclotron, Education, Radionuclide, Radiopharmaceutical, Cancer, Hope, ASX, Innovation, Research, COVID, Antibody, International trade, TLX, US, Patient, Laboratory, Diagnosis, Growth, Digital, Region, Health, CNN International Europe/Middle East/Africa, Isotope, Investment, Medical imaging, Pharmaceutical industry, EU, Telix, Agriculture, Walloon

MELBOURNE, Australia and LIEGE, Belgium, June 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company's radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium.

Key Points: 
  • MELBOURNE, Australia and LIEGE, Belgium, June 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company's radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium.
  • Located in the heart of Belgium's 'Radiopharma Valley', the 2,800 square metre facility is one of Europe's largest radiopharmaceutical production facilities.
  • Often referred to as "theranostics", this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients.
  • Each year more than 10 million imaging procedures are performed in the EU using radiopharmaceutical agents.

Telix to Present at Jefferies Healthcare Conference

Retrieved on: 
Tuesday, June 6, 2023
Webcast, AEST, ASX, Conference, TLX, Telix

MELBOURNE, Australia, June 5, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023.

Key Points: 
  • MELBOURNE, Australia, June 5, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023.
  • The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8).
  • A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440
    The webcast will be accessible on demand on the Telix website following the event.

Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology

Retrieved on: 
Thursday, May 25, 2023
Radiation, Therapy, The Yale Club of New York City, IX, ASX, TLX, Nuclear medicine, Urology, Pharmaceutical industry, Telix

MELBOURNE, Australia and INDIANAPOLIS, May 25, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT. 

Key Points: 
  • Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.
  • Speakers will include members of the Telix leadership team, including Managing Director and Group CEO Dr Christian Behrenbruch and U.S.-based executives, Chief Medical Officer Dr Colin Hayward and Telix Americas CEO, Kevin Richardson.
  • The event will also feature key opinion leaders in urology and nuclear medicine to discuss the clinical utility and opportunity for Telix's investigational products.
  • Note: This event is for qualified institutional investors and analysts.

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

Retrieved on: 
Monday, May 1, 2023
Surgeon, UCLA Institute for Research on Labor and Employment, AUA, American Urological Association, ASX, Associate, TLX, Renal cell carcinoma, MD, Urology, Patient, CST, PET/CT, Phase, Pharmaceutical industry, Medical imaging, Telix

New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.

Key Points: 
  • New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.
  • In very small renal lesions (≤2cm, a secondary endpoint), sensitivity was 84% for all three readers, with specificity 92.3% to 100%.
  • Associate Professor Brian Shuch, MD commented, "It is a great pleasure to be showcasing new data from Telix's Phase III ZIRCON study at AUA, the largest gathering of urologists in the world.
  • We now have analyses on the outcome for very small renal masses, where the data set still shows outstanding sensitivity and specificity, far exceeding confirmatory trial success targets.

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

Retrieved on: 
Monday, May 1, 2023
Surgeon, UCLA Institute for Research on Labor and Employment, AUA, American Urological Association, ASX, Associate, TLX, Renal cell carcinoma, MD, Urology, Patient, CST, PET/CT, Phase, Pharmaceutical industry, Medical imaging, Telix

New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.

Key Points: 
  • New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.
  • In very small renal lesions (≤2cm, a secondary endpoint), sensitivity was 84% for all three readers, with specificity 92.3% to 100%.
  • Associate Professor Brian Shuch, MD commented, "It is a great pleasure to be showcasing new data from Telix's Phase III ZIRCON study at AUA, the largest gathering of urologists in the world.
  • We now have analyses on the outcome for very small renal masses, where the data set still shows outstanding sensitivity and specificity, far exceeding confirmatory trial success targets.

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Retrieved on: 
Thursday, March 16, 2023
Shanda, Cancer, Radiation, New Drug Application, TLX, Dysplasia, Nausea, PET, Lymph, Serum, Risk, Diarrhea, Novartis, Prostate cancer, Osteophyte, CT, PSMA, Patient, Judgement, Paget, PSA, Gallium, Dizziness, FDA, Paget's disease, Disease, Safety, ASX, Pharmaceutical industry, Medical imaging, Telix, Gallium (68Ga) gozetotide

Kevin Richardson, Chief Executive Officer for Telix Americas said, "We welcome the FDA's decision to expand the label indication for Illuccix.

Key Points: 
  • Kevin Richardson, Chief Executive Officer for Telix Americas said, "We welcome the FDA's decision to expand the label indication for Illuccix.
  • This additional indication further demonstrates our continued commitment to support patients fighting prostate cancer and to empower the doctors who treat them.
  • Use of Illuccix in the VISION Phase III study (ClinicalTrials.gov Identifier: NCT03511664 )[4] helped doctors detect prostate cancer and identify the appropriate patients for PSMA-based radioligand therapy.
  • There's no doubt that appropriate selection of patients for PSMA targeted radioligand therapy is dependent on appropriate imaging.

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Retrieved on: 
Thursday, March 16, 2023
Shanda, New Drug Application, TLX, PET, Novartis, Prostate cancer, CT, PSMA, Patient, FDA, Disease, Gallium, ASX, Pharmaceutical industry, Medical imaging, Telix, Gallium (68Ga) gozetotide

To qualify for radioligand therapy, patients must be imaged with an approved gallium-based PSMA-PET agent.

Key Points: 
  • To qualify for radioligand therapy, patients must be imaged with an approved gallium-based PSMA-PET agent.
  • Kevin Richardson, Chief Executive Officer for Telix Americas said, "We welcome the FDA's decision to expand the label indication for Illuccix.
  • There's no doubt that appropriate selection of patients for PSMA targeted radioligand therapy is dependent on appropriate imaging.
  • It is estimated that 32,000 patients per year in the U.S. may be considered for PSMA-directed radioligand therapy.

Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

Retrieved on: 
Sunday, January 8, 2023
Growth, Prostate cancer, Conference, Kidney, TLX, US, ASX, Pharmaceutical industry, Telix

As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).

Key Points: 
  • As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).
  • This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch.
  • Group CEO and Managing Director, Dr. Christian Behrenbruch stated, "We are very pleased with the continued sales momentum since launching Illuccix in the United States in April 2022.
  • The presentation will take place on Wednesday 11 January 2023 at 11.00am PST (Thursday 12 January 6.00am AEDT).

Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

Retrieved on: 
Sunday, January 8, 2023
Growth, Prostate cancer, Conference, Kidney, TLX, US, ASX, Pharmaceutical industry, Telix

As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).

Key Points: 
  • As part of the Company's presentation (available to view or download from the investor page of the Telix corporate website here ), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.).
  • This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch.
  • Group CEO and Managing Director, Dr. Christian Behrenbruch stated, "We are very pleased with the continued sales momentum since launching Illuccix in the United States in April 2022.
  • The presentation will take place on Wednesday 11 January 2023 at 11.00am PST (Thursday 12 January 6.00am AEDT).

Telix Announces Executive Leadership Appointments

Retrieved on: 
Sunday, December 4, 2022
GRC, Monash University, AAA, Corporation, Ministry of Education (Malaysia), API, Food, Novartis, ASX, Gallium, Supreme court, Australian Securities Exchange, Commercial, General counsel, Degenerative disease, TGA, Roche, Risk, FDA, Advanced Accelerator Applications, Global Governance, Law of the United Kingdom, Graduate diploma, Marketing, Ipsen, TLX, Pharmaceutical industry, Management, Telix, Science

MELBOURNE, Australia, Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.

Key Points: 
  • MELBOURNE, Australia, Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.
  • Telix also announces that Genevieve Ryan joins as Group Company Secretary, effective today, 5 December 2022.
  • Dr. Christian Behrenbruch, Telix Group CEO and Managing Director said, "These leadership appointments are a result of ongoing succession planning to ensure Telix has an optimal mix of skills and experience as we prepare to enter a new phase with a portfolio of multiple commercial products.
  • Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan.